G1 therapeutics, inc. (GTHX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flows from operating activities
Net loss

-31,023

-35,441

-32,364

-30,690

-23,952

-24,091

-19,918

-20,869

-20,410

-16,981

-15,601

-15,194

-12,345

Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization

159

141

86

65

64

60

48

35

32

30

27

20

12

Stock-based compensation

4,727

4,463

4,441

3,741

3,804

3,254

3,276

2,101

1,594

1,037

1,040

769

548

Loss on disposal of fixed assets

-8

-

-

-

-

-

-

-

-

-

-

-

-

Increase in fair value of warrant activity

-

-

-

-

-

-

-

-

-

0

0

0

41

Change in operating assets and liabilities
Prepaid expenses and other assets

-1,371

-553

-1,056

1,984

-156

-623

-303

866

-53

194

-438

-163

660

Accounts payable

992

-2,326

3,287

-82

-631

646

-648

-634

-366

-

-

-

-

Accrued expenses and other liabilities

-3,259

-

-1,632

6,062

-987

-

107

2,073

987

-

-

-

-

Deferred Rent

-

-

-

-

-

0

13

2

1

-

-

-

-

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

1,505

3,124

Net cash used in operating activities

-27,025

-30,011

-25,126

-22,888

-21,546

-21,228

-16,810

-18,160

-18,109

-14,746

-13,756

-12,737

-9,280

Cash flows from investing activities
Purchases of property and equipment

-

1,100

1,224

176

216

111

414

113

71

24

236

21

13

Net cash used in investing activities

-

-600

-1,224

-676

-216

-111

-414

-113

-71

-24

-236

-21

-13

Cash flows from financing activities
Proceeds from stock options and warrants exercised

219

386

1,372

678

269

383

506

261

647

202

0

12

1

Proceeds from public offering, net of underwriting fees and commissions

-

-

-

-

-

0

219,106

12,059

108,424

-

-

-

-

Payment of public offering costs

-

-

-

-

-

278

91

207

316

0

303

809

286

Net cash provided by financing activities

219

386

1,372

678

269

105

219,521

12,113

108,755

202

-303

107,706

-285

Net change in cash and cash equivalents

-26,806

-30,225

-24,978

-22,886

-21,493

-21,234

202,297

-6,160

90,575

-14,568

-14,295

94,948

-9,578

Non-cash investing and financing activities
Upfront project costs and other current assets in accounts payable

27

-

-

-

315

-

-

-

-

-

-

-

-

Accretion of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

0

0

289

4,468

Purchases of equipment in accounts payable and accrued expenses

-

-1,039

974

52

54

81

-72

82

9

-

-

-

-

Costs for public offering in accounts payable and accrued expenses

-

-

-

-

-

-

149

-24

172

-

-

-175

478